Patients who present with ventricular tachyarrhythmias constitute a diverse group in which a variety of factors may combine to cause ventricular tachycardia or fibrillation. For this reason, we believe that each patient should undergo a comprehensive medical evaluation directed at identifying and treating such factors as ischemia, congestive heart failure, valvular heart disease, sensitivity to cardioactive drugs, and metabolic derangements. Antiarrhythmic treatment is not necessary for many patients with simple VPBs. However, certain patients who have already suffered a life-threatening arrhythmia or who are at high risk for such arrhythmias should be vigorously treated with specific antiarrhythmic therapy. Such therapy must be carefully selected for each individual. The efficacy of any antiarrhythmic treatment should be assessed by ECG monitoring, exercise testing, or electrophysiologic study. In studies reported to date, antiarrhythmic therapy guided by these methods greatly reduced the risk of recurrent arrhythmias. It is too early to assess the impact of these techniques on overall long-term survival in the various patient populations studied.
Read full abstract